Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemia
Blood (2007) 109 (11): 4635–4640.
Currently there are no citedby results. Try again later.
